Gland Pharma Ltd. (IN:GLAND)
:GLAND
Want to see IN:GLAND full AI Analyst Report?
GLAND Stock Chart & Stats
₹1713.95
-₹19.65(-1.06%)
At close: 4:00 PM EST
₹1713.95
-₹19.65(-1.06%)
Day’s Range― - ―
52-Week Range₹1,458.85 - ₹2,295.00
Previous CloseN/A
Volume93.91K
Average Volume (3M)9.08K
Market Cap
₹365.86B
Enterprise Value₹335.30B
Total Cash (Recent Filing)₹27.04B
Total Debt (Recent Filing)₹3.02B
Price to Earnings (P/E)27.2
Beta0.65
Next Earnings
Aug 11, 2026Next Dividend Ex-DateN/A
Dividend Yield1.07%
Share Statistics
EPS (TTM)47.97
Shares Outstanding164,756,420
10 Day Avg. Volume10,062
30 Day Avg. Volume9,084
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)2.70
Price to Sales (P/S)4.35
P/FCF Ratio37.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,080.00Price Target Upside21.36% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)72.9
Revenue Forecast (FY)₹72.60B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity base give Gland durable financial flexibility. This reduces refinancing and solvency risk, supports capex for sterile capacity and R&D, and allows the company to absorb shocks or pursue strategic investments without jeopardizing operations over the next several quarters.
Improving Cash GenerationA marked rise in operating cash flow and an ~85% jump in free cash flow signal stronger internal funding for growth and maintenance. Improved cash generation enhances the firm's ability to fund capacity, support contract manufacturing commitments, and provide financial resilience versus relying on external financing.
CDMO / Sterile Injectables FocusSpecialization in sterile and complex injectables addresses high-barrier, regulated niches with steady hospital demand. CDMO exposure creates multi-year revenue visibility from contracts and regulatory dossiers across markets, underpinning a defensible business model and structural demand resilience.
Bears Say
Gross Margin VolatilityA dramatic drop in gross margin points to structural pressure from cost increases, product-mix shifts, or pricing erosion. Sustained lower gross margins would weaken operating leverage, compress EBITDA and net margins, and impair the firm's ability to sustainably generate high returns and finance growth internally.
Profitability Below Prior PeakEarnings not recovering to FY2022 peaks despite revenue growth implies margin deterioration or one-off drains. Persistently lower profitability limits return on equity and free cash available for reinvestment or shareholder distributions, raising questions about durable earnings quality.
Moderate Cash ConversionCash conversion below EBITDA and FCF at ~60% of net income suggests working capital or capex consumption reduces cash that earnings imply. This inconsistent conversion constrains the firm's ability to reliably self-fund expansion, smooth dividends, or rapidly de-lever during downturns.
Gland Pharma Ltd. News
GLAND FAQ
What was Gland Pharma Ltd.’s price range in the past 12 months?
Gland Pharma Ltd. lowest stock price was ₹1458.85 and its highest was ₹2295.00 in the past 12 months.
What is Gland Pharma Ltd.’s market cap?
Gland Pharma Ltd.’s market cap is ₹365.86B.
When is Gland Pharma Ltd.’s upcoming earnings report date?
Gland Pharma Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Gland Pharma Ltd.’s earnings last quarter?
Gland Pharma Ltd. released its earnings results on May 15, 2026. The company reported ₹22.3 earnings per share for the quarter, beating the consensus estimate of ₹16.252 by ₹6.048.
Is Gland Pharma Ltd. overvalued?
According to Wall Street analysts Gland Pharma Ltd.’s price is currently Undervalued.
Does Gland Pharma Ltd. pay dividends?
Gland Pharma Ltd. pays a Notavailable dividend of ₹18 which represents an annual dividend yield of 1.07%. See more information on Gland Pharma Ltd. dividends here
What is Gland Pharma Ltd.’s EPS estimate?
Gland Pharma Ltd.’s EPS estimate is 17.
How many shares outstanding does Gland Pharma Ltd. have?
Gland Pharma Ltd. has 164,756,420 shares outstanding.
What happened to Gland Pharma Ltd.’s price movement after its last earnings report?
Gland Pharma Ltd. reported an EPS of ₹22.3 in its last earnings report, beating expectations of ₹16.252. Following the earnings report the stock price went down -1.48%.
Which hedge fund is a major shareholder of Gland Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:GLAND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gland Pharma Ltd.
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
GLAND Stock 12 Month Forecast
Average Price Target
₹2,080.00
▲(21.36% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―